Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$6.40 – $15.29
97% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $6.7K | $6.7K | $0 | $0 | $3.2M | $3.2M | $527.0K | $0 |
| Gross profit | −$6.7K | −$6.7K | $0 | $0 | −$3.2M | −$3.2M | −$527.0K | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $0 | $0 | $18.6M | $34.8M | $36.2M | $49.0M | $65.3M | $117.7M |
| Operating income | −$861.9K | −$468.2K | −$33.0M | −$93.9M | −$66.3M | −$93.9M | −$103.9M | −$166.3M |
| EBITDA | −$851.3K | −$1.1M | −$33.6M | −$91.2M | −$63.2M | −$92.6M | −$105.9M | −$178.3M |
| Net income | −$857.9K | −$1.1M | −$34.1M | −$93.0M | −$56.8M | −$95.7M | −$108.7M | −$183.8M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -2.74 | -2.94 | -1.92 | -3.40 | -1.84 | -2.44 | -0.15 | -2.06 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $17M | $-1.94 | $-2.40–$-1.16 | 9 |
| 2027 | $56M | $-1.82 | $-2.31–$-0.53 | 12 |
| 2028 | $216M | $-0.54 | $-1.89–$2.95 | 10 |
| 2029 | $493M | $0.99 | $0.99–$0.99 | 4 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds MNMD.
No tracked institution reports a position in MNMD as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-08-29 | 1-for-15reverse |
No one on the platform has traded MNMD yet.
| $2.0B |
| — |
| NRIXNurix Therapeutics, Inc. | $23.85 | +4.15% | $2.1B | — |
| RZLTRezolute, Inc. | $5.10 | +1.19% | $491M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.